- LCB to receive $10 M as upfront, and up to $353.5M as cumulative milestone payments along with royalties on sales of LCB71. CStone get an exclusive global right to lead the development and commercialization of LCB71 outside the Republic of Korea
- The collaboration adds the first ADC to CStone’s development pipeline, bolstering its precision medicine franchise with a new modality
- LCB71 is a pre-clinical ADC targeting ROR1, having the potential to treat multiple cancer indications and has demonstrated efficacy and reduced toxicity in preclinical studies
Click here to read full press release/ article | Ref: PRNewswire | Image: Investopedia
The post CStone Signs a License Agreement with LegoChem for LCB71 to Treat Multiple Cancer Indications first appeared on PharmaShots.